Skip to main content
OpenTrials

Clinical trial condition

RAS Mutation

Explore clinical trials studying RAS Mutation. Study availability and eligibility vary by location and protocol.

12 public trials 8 recruiting studies
Refine in advanced search Browse all conditions

RAS Mutation trial results

Recruiting

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

NCT04678648

Conditions
Advanced Malignant Solid Neoplasm, Astrocytoma, Colon Cancer, +35 more
Locations
  • University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology Los Angeles, California, United States
  • Sarah Cannon, SCRI Oncology Partners - Health One Denver, Colorado, United States
  • Sarah Cannon, SCRI Oncology Partners Nashville, Tennessee, United States
View Trial Details
Recruiting

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

NCT06922591

Conditions
Lung Cancer, Lung Diseases, Lung Neoplasms, +12 more
Locations
  • Mayo Clinic Scottsdale Scottsdale, Arizona, United States
  • Sarah Cannon Research Institute Denver Denver, Colorado, United States
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • Mayo Clinic Jacksonville Jacksonville, Florida, United States
View all 18 locations
View Trial Details
Recruiting

RASopathy Biorepository

NCT04395495

Conditions
Abnormalities, Multiple, Cardiofaciocutaneous Syndrome, Cardiofaciocutaneous syndrome, +48 more
Locations
  • Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States
View Trial Details
Recruiting

PAS-004 in Patients With Advanced Solid Tumors

NCT06299839

Conditions
Advanced Solid Tumors, NF1 Mutation, Neoplasms, +2 more
Locations
  • NEXT Oncology Austin, Texas, United States
  • NEXT Oncology Irving, Texas, United States
  • NEXT Oncology San Antonio, Texas, United States
  • NEXT Oncology Fairfax, Virginia, United States
View Trial Details
Not Yet Recruiting

A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

NCT07678593

Conditions
Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation
Locations
  • Concord Cancer Centre, Concord Repatriation General Hospital, Sydney Local Health District Concord, New South Wales, Australia
  • Macquarie University / Clinical Trials Unit North Ryde, New South Wales, Australia
  • The Queen Elizabeth Hospital Woodville South, South Australia, Australia
  • Monash Health (Monash Medical Centre) Clayton, Victoria, Australia
View all 17 locations
View Trial Details

Related conditions